BioSpace News Archive

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its wholly owned subsidiary TumorGenesis, Inc. in the last quarter has sold media to two top research medical centers, one in New York City and the other in Boston, Massachusetts

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today highlighted its business and clinical progress in 2020 and expected 2021 milestones.

Echosens, a high-technology company offering the FibroScan family of products, announces acceptance of its article for publication of the findings of an independent assessment conducted by Santa Barbara Actuaries Inc. (SBA) to evaluate from the payer’s perspective the cost effectiveness of deploying VCTE / CAP machines (FibroScan®) for detecting and monitoring fatty liver disease (FLD). Scheduled for publication in 2021 by the American Journal of Managed Care,

Nucleai (www.Nucleaimd.com), a global provider in pathology-based biomarker discovery, and Debiopharm (www.debiopharm.com), a Swiss-based biopharmaceutical company specializing in drug development, announced that they have entered into a long-term collaboration to leverage Nucleai’s artificial intelligence (AI) -powered biomarker research & discovery platform for one of Debiopharm’s clinical stage oncology assets.

Global health service company Cigna Corporation (NYSE:CI) will release its fourth quarter 2020 financial results on Thursday, Feb. 4, 2021, and will host a conference call the same day.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the first patient has been enrolled in Mirum’s Phase 2b VISTAS study evaluating volixibat in adult patients with primary sclerosing cholangitis (PSC), an idiopathic chronic cholestatic liver disease characterized by progressive inflammation and destruction of bile ducts often leading to serious liver disease, cancer, and ultimately liver failure.

The first survey results reveal physicians seek new diagnostic tools and insights to improve COVID-19 management and patient outcomes

The leading life sciences R&D cloud added 150 customers, including biotech innovators Gilead Sciences, Sanofi, and UCB

Koya Medical ( www.koyamedical.com ), a healthcare company focused on treating lymphedema and vein disease, today announced the close of a $11 million Series A investment round. The new investment was led by Arboretum Ventures. Jan Garfinkle , founder and managing director of Arboretum Ventures will join the board of directors

Frontage Laboratories and Frontage Clinical Services are pleased to announce plans to provide full service human radiolabeled Absorption, Metabolism, and Excretion study capabilities, subject to receipt of required regulatory approvals.